A Case of Adjuvant Brigatinib in a Patient with ALK-rearranged R0 Resected Oligometastatic Lung Cancer

Adjuvant Brigatinib Treatment in Lung Cancer

Authors

  • Oktay Ünsal Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Türkiye
  • Nalan Akyürek Department of Pathology, Gazi University Faculty of Medicine, Ankara, Türkiye
  • Osman Yüksel Deparment of General Surgery, Gazi University Faculty of Medicine, Ankara, Türkiye
  • Abdullah İrfan Taştepe Deparment of Thoracic Surgery, Gazi University Faculty of Medicine, Ankara, Türkiye
  • Ahmet Özet Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Türkiye

Keywords:

ALK rearrangement, brigatinib, lung cancer, oligometastasis, targeted therapy

Abstract

Anaplastic lymphoma kinase (ALK) rearrangement is detected at a low rate in non-small cell lung cancer (NSCLC). Patients with ALK rearrangements have poor responses to conventional cytotoxic chemotherapy. Brigatinib is one of the ALK-tyrosine kinase inhibitors recommended for first-line treatment in metastatic NSCLC. Local ablative therapies are applied in the treatment of oligometastatic disease in NSCLC. In this case, a patient with lung adenocarcinoma with ALK-rearranged isolated adrenal metastasis was treated with adjuvant brigatinib after sequential surgery. A 23-month disease-free survival was obtained. The case reported here represents the use of adjuvant therapy with ALK inhibitors in ALK-positive oligometastatic NSCLC in eligible patients.

Downloads

Published

13.10.2025

Issue

Vol. 36 No. 4 (2025): Gazi Medical Journal

Section

Case Report

Most read articles by the same author(s)

1 2 > >>